Compare Garmin Ltd. (GRMN) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Hinge Health Inc. Class A Common Stock — how do they compare? Garmin Ltd. trades at $281.37 (market cap $53.31B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Garmin Ltd. is far larger — about 6.3× Hinge Health Inc. Class A Common Stock's market cap, and Garmin Ltd. pays a 1.52% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 84 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GRMN | HNGE | |
|---|---|---|
Market Cap | $53.31B | $8.48B |
Volume | 778,898 | 879,799 |
Sector | Technology | Health |
52-Week High | $313.16 | $105.14 |
52-Week Low | $187.10 | $31.17 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $50.82B | $8.10B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $279.72, up 4.86% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bearish technical signals but maintains robust fundamentals with 24.47% net margins and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive news includes product awards and institutional accumulation, though technical indicators suggest near-term resistance.
GRMN presents a mixed outlook: strong profitability and analyst consensus target of $320.25 offer 14.5% upside, but bearish technicals and high valuation ratios (P/E 28.53) pose risks. Investment appeal hinges on execution of 2026 revenue guidance ($7.7B) amid competitive pressures in consumer electronics.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
